Skip to main content

Advertisement

SpringerLink
Log in

Gene Editing in Human Haematopoietic Stem Cells for the Treatment of Primary Immunodeficiencies

  • Review Article
  • Published:
Molecular Diagnosis & Therapy Aims and scope Submit manuscript

Abstract

In recent years, gene-editing technologies have revolutionised precision medicine, and human trials of this technology have been reported in cell-based cancer therapies and other genetic disorders. The same techniques have the potential to reverse mutations in monogenic primary immunodeficiencies (PIDs), and transplantation of edited haematopoietic stem cells may provide a functional cure for these diseases. In this review, we discuss the methods of gene editing being explored and describe progress made so far with several PIDs. We also detail the remaining challenges, how to confidently detect off-target effects and chromosomal abnormalities in a timely manner, how to obtain long-term benefits, and how to achieve physiological levels of expression of the therapeutic gene. With advances in gene editing, we envisage a robust clinical translation of this technology in the coming decade.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Abolhassani H, Azizi G, Sharifi L, Yazdani R, Mohsenzadegan M, Delavari S, et al. Global systematic review of primary immunodeficiency registries. Expert Rev Clin Immunol. 2020;16:717–32.

    Article  CAS  Google Scholar 

  2. Shehata N, Palda V, Bowen T, Haddad E, Issekutz TB, Mazer B, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev. 2010;24(Suppl 1):S28-50.

    Article  Google Scholar 

  3. Hahn T, McCarthy PL, Hassebroek A, Bredeson C, Gajewski JL, Hale GA, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013;31:2437–49.

    Article  Google Scholar 

  4. Touzot F, Hacein-Bey-Abina S, Fischer A, Cavazzana M. Gene therapy for inherited immunodeficiency. Expert Opin Biol Ther. 2014;14:789–98.

    Article  CAS  Google Scholar 

  5. Baum C. Insertional mutagenesis in gene therapy and stem cell biology. Curr Opin Hematol. 2007;14:337–42.

    Article  CAS  Google Scholar 

  6. Doudna JA. The promise and challenge of therapeutic genome editing. Nature. Nature Publishing Group; 2020;578:229–36.

  7. Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA. 1996;93:1156.

    Article  CAS  Google Scholar 

  8. Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S, et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science. 2009;326:1509–12.

    Article  CAS  Google Scholar 

  9. Jansen R, van Embden JDA, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002;43:1565–75.

    Article  CAS  Google Scholar 

  10. Mojica FJM, Díez-Villaseñor C, García-Martínez J, Soria E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol. 2005;60:174–82.

    Article  CAS  Google Scholar 

  11. Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature Nature Publishing Group. 2011;471:602–7.

    CAS  Google Scholar 

  12. Porto EM, Komor AC, Slaymaker IM, Yeo GW. Base editing: advances and therapeutic opportunities. Nat Rev Drug Discov. 2020;19:839–59.

    Article  CAS  Google Scholar 

  13. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149–57.

    Article  CAS  Google Scholar 

  14. Wang J, He Z, Wang G, Zhang R, Duan J, Gao P, et al. Efficient targeted insertion of large DNA fragments without DNA donors. Nat Methods. 2022;19:331–40.

    Article  CAS  Google Scholar 

  15. Xu L, Yang H, Gao Y, Chen Z, Xie L, Liu Y, et al. CRISPR/Cas9-mediated CCR5 ablation in human hematopoietic stem/progenitor cells confers HIV-1 resistance in vivo. Mol Ther. 2017;25:1782–9.

    Article  CAS  Google Scholar 

  16. Frangoul H, Altshuler D, Cappellini MD, Chen Y-S, Domm J, Eustace BK, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384:252–60.

    Article  CAS  Google Scholar 

  17. Florea AED, Braylan RC, Schafernak KT, Williams KW, Daub J, Goyal RK, et al. Abnormal B-cell maturation in the bone marrow of patients with germline mutations in PIK3CD. J Allergy Clin Immunol. 2017;139:1032-1035.e6.

    Article  Google Scholar 

  18. Horwitz MS, Corey SJ, Grimes HL, Tidwell T. ELANE Mutations in cyclic and severe congenital neutropenia—genetics and pathophysiology. Hematol Oncol Clin N Am. 2013;27:19–41.

    Article  Google Scholar 

  19. Nasri M, Ritter M, Mir P, Dannenmann B, Aghaallaei N, Amend D, et al. CRISPR/Cas9-mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients. Haematologica. 2020;105:598–609.

    Article  CAS  Google Scholar 

  20. Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385:493–502.

    Article  CAS  Google Scholar 

  21. Sacco MG, Ungari M, Catò EM, Villa A, Strina D, Notarangelo LD, et al. Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome. Cancer Gene Ther. 2000;7:1299–306.

    Article  CAS  Google Scholar 

  22. Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Sig Transduct Target Ther. 2021;6:1–24.

    Article  Google Scholar 

  23. Rigo F, Martinson HG. Functional coupling of last-intron splicing and 3’-end processing to transcription in vitro: the poly(A) signal couples to splicing before committing to cleavage. Mol Cell Biol. 2008;28:849–62.

    Article  CAS  Google Scholar 

  24. Nesic D, Cheng J, Maquat LE. Sequences within the last intron function in RNA 3’-end formation in cultured cells. Mol Cell Biol. 1993;13:3359–69.

    CAS  Google Scholar 

  25. Gray DH, Villegas I, Long J, Santos J, Keir A, Abele A, et al. Optimizing integration and expression of transgenic Bruton’s tyrosine kinase for CRISPR-Cas9-mediated gene editing of X-linked agammaglobulinemia. CRISPR J. 2021;4:191–206.

    Article  CAS  Google Scholar 

  26. Rapti K, Stillitano F, Karakikes I, Nonnenmacher M, Weber T, Hulot J-S, et al. Effectiveness of gene delivery systems for pluripotent and differentiated cells. Mol Ther Methods Clin Dev. 2015;2:14067.

  27. Schiroli G, Conti A, Ferrari S, Della Volpe L, Jacob A, Albano L, et al. Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response. Cell Stem Cell. 2019;24:551-565.e8.

    Article  CAS  Google Scholar 

  28. Sadelain M, Papapetrou EP, Bushman FD. Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer. 2011;12:51–8.

    Article  Google Scholar 

  29. Sander JD, Zaback P, Joung JK, Voytas DF, Dobbs D. Zinc Finger Targeter (ZiFiT): an engineered zinc finger/target site design tool. Nucleic Acids Res. 2007;35:W599-605.

    Article  Google Scholar 

  30. Heigwer F, Kerr G, Walther N, Glaeser K, Pelz O, Breinig M, et al. E-TALEN: a web tool to design TALENs for genome engineering. Nucleic Acids Res. 2013;41: e190.

    Article  CAS  Google Scholar 

  31. Heigwer F, Kerr G, Boutros M. E-CRISP: fast CRISPR target site identification. Nat Methods. 2014;11:122–3.

    Article  CAS  Google Scholar 

  32. Körbling M, Freireich EJ. Twenty-five years of peripheral blood stem cell transplantation. Blood. 2011;117:6411–6.

    Article  Google Scholar 

  33. Dreger P, Haferlach T, Eckstein V, Jacobs S, Suttorp M, Löffler H, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol. 1994;87:609–13.

    Article  CAS  Google Scholar 

  34. Etard C, Joshi S, Stegmaier J, Mikut R, Strähle U. Tracking of indels by DEcomposition is a simple and effective method to assess efficiency of guide RNAs in zebrafish. Zebrafish. 2017;14:586–8.

    Article  CAS  Google Scholar 

  35. Conant D, Hsiau T, Rossi N, Oki J, Maures T, Waite K, et al. Inference of CRISPR edits from sanger trace data. CRISPR J. 2022;5:123–30.

    Article  CAS  Google Scholar 

  36. Mashal RD, Koontz J, Sklar J. Detection of mutations by cleavage of DNA heteroduplexes with bacteriophage resolvases. Nat Genet. 1995;9:177–83.

    Article  CAS  Google Scholar 

  37. Sentmanat MF, Peters ST, Florian CP, Connelly JP, Pruett-Miller SM. A survey of validation strategies for CRISPR-Cas9 editing. Sci Rep. 2018;8:888.

    Article  Google Scholar 

  38. Peng C, Zheng M, Ding L, Chen X, Wang X, Feng X, et al. Accurate detection and evaluation of the gene-editing frequency in plants using droplet digital PCR. Front Plant Sci [Internet]. 2020. https://doi.org/10.3389/fpls.2020.610790.

    Article  Google Scholar 

  39. Cheng Y, Tsai SQ. Illuminating the genome-wide activity of genome editors for safe and effective therapeutics. Genome Biol. 2018;19:226.

    Article  CAS  Google Scholar 

  40. Bae S, Park J, Kim J-S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics. 2014;30:1473–5.

    Article  CAS  Google Scholar 

  41. Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2015;33:187–97.

    Article  CAS  Google Scholar 

  42. Tsai SQ, Nguyen NT, Malagon-Lopez J, Topkar VV, Aryee MJ, Joung JK. CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR–Cas9 nuclease off-targets. Nat Methods. 2017;14:607–14.

    Article  CAS  Google Scholar 

  43. Lazzarotto CR, Nguyen NT, Tang X, Malagon-Lopez J, Guo JA, Aryee MJ, et al. Defining CRISPR–Cas9 genome-wide nuclease activities with CIRCLE-seq. Nat Protoc. 2018;13:2615–42.

    Article  CAS  Google Scholar 

  44. Turchiano G, Andrieux G, Klermund J, Blattner G, Pennucci V, el Gaz M, et al. Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. Cell Stem Cell. 2021;28:1136-1147.e5.

    Article  CAS  Google Scholar 

  45. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science. 2016;351:84–8.

    Article  CAS  Google Scholar 

  46. Vakulskas CA, Dever DP, Rettig GR, Turk R, Jacobi AM, Collingwood MA, et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med. 2018;24:1216–24.

    Article  CAS  Google Scholar 

  47. Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529:490–5.

    Article  CAS  Google Scholar 

  48. Leibowitz ML, Papathanasiou S, Doerfler PA, Blaine LJ, Sun L, Yao Y, et al. Chromothripsis as an on-target consequence of CRISPR–Cas9 genome editing. Nat Genet. 2021;53:895–905.

    Article  CAS  Google Scholar 

  49. Kraus H, Kaiser S, Aumann K, Bönelt P, Salzer U, Vestweber D, et al. A feeder-free differentiation system identifies autonomously proliferating B cell precursors in human bone marrow. J Immunol. 2014;192:1044–54.

    Article  CAS  Google Scholar 

  50. Wognum B, Yuan N, Lai B, Miller CL. Colony forming cell assays for human hematopoietic progenitor cells. Methods Mol Biol. 2013;946:267–83.

    Article  CAS  Google Scholar 

  51. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174:6477–89.

    Article  CAS  Google Scholar 

  52. Ramkumar C, Gerstein RM, Zhang H. Serial transplantation of bone marrow to test self-renewal capacity of hematopoietic stem cells in vivo. Methods Mol Biol. 2013;976:17–24.

    Article  CAS  Google Scholar 

  53. Sweeney CL, Pavel-Dinu M, Choi U, Brault J, Liu T, Koontz S, et al. Correction of X-CGD patient HSPCs by targeted CYBB cDNA insertion using CRISPR/Cas9 with 53BP1 inhibition for enhanced homology-directed repair. Gene Ther. 2021;28:373–90.

    Article  CAS  Google Scholar 

  54. Urnov FD, Miller JC, Lee Y-L, Beausejour CM, Rock JM, Augustus S, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature. 2005;435:646–51.

    Article  CAS  Google Scholar 

  55. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee Y-L, Kim KA, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol. 2007;25:1298–306.

    Article  CAS  Google Scholar 

  56. Schiroli G, Ferrari S, Conway A, Jacob A, Capo V, Albano L, et al. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. Sci Transl Med. 2017;9:eaan0820.

    Article  Google Scholar 

  57. Pavel-Dinu M, Wiebking V, Dejene BT, Srifa W, Mantri S, Nicolas CE, et al. Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nat Commun. 2019;10:1634.

    Article  Google Scholar 

  58. Chang C-W, Lai Y-S, Westin E, Khodadadi-Jamayran A, Pawlik KM, Lamb LS, et al. Modeling human severe combined immunodeficiency and correction by CRISPR/Cas9-enhanced gene targeting. Cell Rep. 2015;12:1668–77.

    Article  CAS  Google Scholar 

  59. Hubbard N, Hagin D, Sommer K, Song Y, Khan I, Clough C, et al. Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome. Blood. 2016;127:2513–22.

    Article  CAS  Google Scholar 

  60. Kuo CY, Long JD, Campo-Fernandez B, de Oliveira S, Cooper AR, Romero Z, et al. Site-specific gene editing of human hematopoietic stem cells for X-linked hyper-IgM syndrome. Cell Rep. 2018;23:2606–16.

    Article  CAS  Google Scholar 

  61. Laskowski TJ, Van Caeneghem Y, Pourebrahim R, Ma C, Ni Z, Garate Z, et al. Gene correction of iPSCs from a Wiskott-Aldrich syndrome patient normalizes the lymphoid developmental and functional defects. Stem Cell Reports Elsevier. 2016;7:139–48.

    Article  CAS  Google Scholar 

  62. Gutierrez-Guerrero A, Sanchez-Hernandez S, Galvani G, Pinedo-Gomez J, Martin-Guerra R, Sanchez-Gilabert A, et al. Comparison of zinc finger nucleases versus crispr-specific nucleases for genome editing of the Wiskott-Aldrich syndrome locus. Hum Gene Ther. 2018;29:366–80.

    Article  CAS  Google Scholar 

  63. Rai R, Romito M, Rivers E, Turchiano G, Blattner G, Vetharoy W, et al. Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott-Aldrich Syndrome. Nat Commun. 2020;11:4034.

    Article  CAS  Google Scholar 

  64. Merling RK, Sweeney CL, Chu J, Bodansky A, Choi U, Priel DL, et al. An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous disease. Mol Ther. 2015;23:147–57.

    Article  CAS  Google Scholar 

  65. De Ravin SS, Reik A, Liu P-Q, Li L, Wu X, Su L, et al. Targeted gene addition in human CD34(+) hematopoietic cells for correction of X-linked chronic granulomatous disease. Nat Biotechnol. 2016;34:424–9.

    Article  Google Scholar 

  66. De Ravin SS, Li L, Wu X, Choi U, Allen C, Koontz S, et al. CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. Sci Transl Med. 2017;9:eaah3480.

    Article  Google Scholar 

  67. Sweeney CL, Zou J, Choi U, Merling RK, Liu A, Bodansky A, et al. Targeted repair of CYBB in X-CGD iPSCs requires retention of intronic sequences for expression and functional correction. Mol Ther. 2017;25:321–30.

    Article  CAS  Google Scholar 

  68. Merling RK, Kuhns DB, Sweeney CL, Wu X, Burkett S, Chu J, et al. Gene-edited pseudogene resurrection corrects p47phox-deficient chronic granulomatous disease. Blood Adv. 2016;1:270–8.

    Article  Google Scholar 

  69. Klatt D, Cheng E, Hoffmann D, Santilli G, Thrasher AJ, Brendel C, et al. Differential transgene silencing of myeloid-specific promoters in the AAVS1 safe harbor locus of induced pluripotent stem cell-derived myeloid cells. Hum Gene Ther. 2020;31:199–210.

    Article  CAS  Google Scholar 

  70. Goodwin M, Lee E, Lakshmanan U, Shipp S, Froessl L, Barzaghi F, et al. CRISPR-based gene editing enables FOXP3 gene repair in IPEX patient cells. Sci Adv. 2020;6:eaaz0571.

    Article  CAS  Google Scholar 

  71. Brault J, Liu T, Bello E, Liu S, Sweeney CL, Meis RJ, et al. CRISPR-targeted MAGT1 insertion restores XMEN patient hematopoietic stem cells and lymphocytes. Blood. 2021;138:2768–80.

    Article  CAS  Google Scholar 

  72. Fischer A, Notarangelo LD, Neven B, Cavazzana M, Puck JM. Severe combined immunodeficiencies and related disorders. Nat Rev Dis Primers. 2015;1:1–18.

    Article  CAS  Google Scholar 

  73. Yazdani R, Fekrvand S, Shahkarami S, Azizi G, Moazzami B, Abolhassani H, et al. The hyper IgM syndromes: Epidemiology, pathogenesis, clinical manifestations, diagnosis and management. Clin Immunol. 2019;198:19–30.

    Article  CAS  Google Scholar 

  74. Noelle RJ. CD40 and its ligand in host defense. Immunity. 1996;4:415–9.

    Article  CAS  Google Scholar 

  75. Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore). 2003;82:373–84.

    Article  CAS  Google Scholar 

  76. Calvez R, Lafouresse F, Meester JD, Galy A, Valitutti S, Dupré L. The Wiskott-Aldrich syndrome protein permits assembly of a focused immunological synapse enabling sustained T-cell receptor signaling. Haematologica. 2011;96:1415–23.

    Article  CAS  Google Scholar 

  77. Suri D, Rikhi R, Jindal AK, Rawat A, Sudhakar M, Vignesh P, et al. Wiskott aldrich syndrome: a multi-institutional experience from India. Front Immunol[Internet]. 2021. https://doi.org/10.3389/fimmu.2021.627651.

    Article  Google Scholar 

  78. Arnold DE, Heimall JR. A review of chronic granulomatous disease. Adv Ther. 2017;34:2543–57.

    Article  CAS  Google Scholar 

  79. Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med. 2010;363:2600–10.

    Article  CAS  Google Scholar 

  80. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20–1.

    Article  CAS  Google Scholar 

  81. Park JH, Lee KH, Jeon B, Ochs HD, Lee JS, Gee HY, et al. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: a systematic review. Autoimmun Rev. 2020;19: 102526.

    Article  CAS  Google Scholar 

  82. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. 1993. J Immunol. 2012;188:2936–47.

    CAS  Google Scholar 

  83. Wang Q, Pechersky Y, Sagawa S, Pan AC, Shaw DE. Structural mechanism for Bruton’s tyrosine kinase activation at the cell membrane. Proc Natl Acad Sci USA. 2019;116:9390–9.

    Article  CAS  Google Scholar 

  84. Vetrie D, Vorechovský I, Sideras P, Holland J, Davies A, Flinter F, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226–33.

    Article  CAS  Google Scholar 

  85. El-Sayed ZA, Abramova I, Aldave JC, Al-Herz W, Bezrodnik L, Boukari R, et al. X-linked agammaglobulinemia (XLA): Phenotype, diagnosis, and therapeutic challenges around the world. World Allergy Organ J. 2019;12: 100018.

    Article  CAS  Google Scholar 

  86. Rohrer J, Conley ME. Correction of X-linked immunodeficient mice by competitive reconstitution with limiting numbers of normal bone marrow cells. Blood. 1999;94:3358–65.

    Article  CAS  Google Scholar 

  87. Li F-Y, Chaigne-Delalande B, Su H, Uzel G, Matthews H, Lenardo MJ. XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood. 2014;123:2148–52.

    Article  CAS  Google Scholar 

  88. Braun CJ, Witzel M, Paruzynski A, Boztug K, von Kalle C, Schmidt M, et al. Gene therapy for Wiskott-Aldrich Syndrome—long-term reconstitution and clinical benefits, but increased risk for leukemogenesis. Rare Dis. 2014;2:e947749.

    Article  Google Scholar 

  89. Omer-Javed A, Pedrazzani G, Albano L, Ghaus S, Latroche C, Manzi M, et al. Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells. Cell. 2022;185:2248–2264.e21.

  90. Drago D, Foss-Campbell B, Wonnacott K, Barrett D, Ndu A. Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs. Mol Ther Methods Clin Dev. 2021;21:524–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, University College London, London, UK

    Sameer Bahal, Klesti Karaxhuku & Giorgia Santilli

  2. NIHR Great Ormond Street Hospital Biomedical Research Centre, London, UK

    Giorgia Santilli

Authors
  1. Sameer Bahal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Klesti Karaxhuku
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giorgia Santilli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Sameer Bahal or Giorgia Santilli.

Ethics declarations

Funding

No funding was received for this article.

Conflicts of interest

Sameer Bahal, Klesti Karaxhuku and Giorgia Santilli declare that they have no conflicts of interest.

Ethics approval and consent

Not applicable.

Data availability

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Code availability

Not applicable.

Author contributions

SB and KK wrote the manuscript. GS wrote and edited the manuscript.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bahal, S., Karaxhuku, K. & Santilli, G. Gene Editing in Human Haematopoietic Stem Cells for the Treatment of Primary Immunodeficiencies. Mol Diagn Ther 27, 15–28 (2023). https://doi.org/10.1007/s40291-022-00618-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40291-022-00618-x

Search

Navigation